Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT): 11 pipeline candidates · ~17 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.5 months
D/E 32.88 · 0% dilution
Lead: Approved
11 candidates
N/A
0 buys · 6 sells (180d)
A transparent, data-derived signal for Editas Medicine, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$392.9M
Cash
$126.3M
Quarterly Burn
$23.1M
Runway
16.5 mo
Revenue
$2.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| Alpha-beta T-cell therapies for cancer | Preclinical |
| CASGEVY | Approved |
| CASGEVY (exagamglogene autotemcel) | Approved |
| cd19 hd allo car t | Phase 1 |
| edit-301 | Phase 1 |
| edit-401 | Phase 1 |
| Gamma-delta T-cell therapies for cancer | Preclinical |
| In vivo HSC gene editing program for SCD and TDT | Preclinical |
| In vivo liver gene editing program | Preclinical |
| reni-cel | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
205
Total value held
$122.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 9,263,312 | $22.9M |
| vanguard capital management llc | 8,408,738 | $20.8M |
| renaissance technologies llc | 3,972,160 | $9.8M |
| vanguard portfolio management llc | 3,148,570 | $7.8M |
| geode capital management, llc | 2,311,789 | $5.7M |
| state street corp | 2,076,122 | $5.1M |
| d. e. shaw & co., inc. | 1,943,893 | $4.8M |
| two sigma investments, lp | 1,549,063 | $3.8M |
| aqr capital management llc | 1,370,497 | $3.4M |
| raymond james financial inc | 1,293,848 | $3.2M |
Showing top 10 of 205 institutional holders of Editas Medicine, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Editas Medicine, Inc.'s pipeline?
Editas Medicine, Inc. (EDIT) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Editas Medicine, Inc.'s lead drug candidate?
Editas Medicine, Inc.'s most advanced tracked candidate is Alpha-beta T-cell therapies for cancer (Preclinical) for Solid and liquid tumors.
What is Editas Medicine, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Editas Medicine, Inc. has approximately 16.5 months of cash runway.
What is Editas Medicine, Inc.'s market capitalization?
Editas Medicine, Inc.'s market capitalization is approximately $392.9M.
Who is the CEO of Editas Medicine, Inc.?
Dr. Gilmore O'Neill M.D. is the chief executive officer of Editas Medicine, Inc. (EDIT).
Get the full picture on Editas Medicine, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.